$2.63 Billion is the total value of SECTORAL ASSET MANAGEMENT INC's 77 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 52.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIIB | Buy | BIOGEN INC | $210,365,000 | +41.0% | 498,212 | +13.4% | 7.99% | +19.4% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $175,593,000 | +55.0% | 1,409,031 | +12.4% | 6.67% | +31.2% |
| CELG | Buy | CELGENE CORP | $139,357,000 | +9.8% | 1,208,858 | +6.6% | 5.29% | -7.0% |
| GILD | Buy | GILEAD SCIENCES INC | $129,581,000 | +100.9% | 1,320,507 | +93.0% | 4.92% | +70.1% |
| INCY | Buy | INCYTE CORPORATION | $122,471,000 | +25.7% | 1,336,144 | +0.2% | 4.65% | +6.4% |
| B108PS | Buy | ACTAVIS PLCshares | $111,431,000 | +68.5% | 374,407 | +45.8% | 4.23% | +42.7% |
| TEVA | Buy | TEVA PHARMACEUTICALadr | $103,454,000 | +30.3% | 1,660,583 | +20.3% | 3.93% | +10.3% |
| TMO | Buy | THERMO FISHER SCIENTIFIC | $78,876,000 | +20.9% | 587,136 | +12.8% | 3.00% | +2.4% |
| MYL | New | MYLAN N V | $71,626,000 | – | 1,206,838 | +100.0% | 2.72% | – |
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $68,683,000 | -3.7% | 396,324 | +2.8% | 2.61% | -18.5% |
| VRTX | Buy | VERTEX PHARMACEUTICALS | $60,118,000 | +138.4% | 509,600 | +140.1% | 2.28% | +101.9% |
| SHPG | Buy | SHIRE PLCsp adr | $59,549,000 | +18.7% | 248,859 | +5.4% | 2.26% | +0.4% |
| FOLD | Buy | AMICUS THERAPEUTICS | $54,249,000 | +36.8% | 4,986,138 | +4.6% | 2.06% | +15.9% |
| HALO | Buy | HALOZYME THERAPEUTICS | $53,229,000 | +48.1% | 3,727,551 | +0.1% | 2.02% | +25.4% |
| RDY | Buy | DR REDDYS LABS LTDadr | $53,044,000 | +37.8% | 928,962 | +21.8% | 2.01% | +16.6% |
| PFE | Buy | PFIZER INC | $51,909,000 | +37.7% | 1,492,057 | +23.3% | 1.97% | +16.6% |
| KERX | Buy | KERYX BIOPHARMACEUTICALS | $48,696,000 | +5.6% | 3,825,256 | +17.4% | 1.85% | -10.5% |
| SGEN | Buy | SEATTLE GENETICS INC | $44,551,000 | +25.6% | 1,260,275 | +14.1% | 1.69% | +6.3% |
| PRGO | Buy | PERRIGO COshares | $44,471,000 | +14.6% | 268,624 | +15.8% | 1.69% | -2.9% |
| PTLA | Buy | PORTOLA PHARMACEUTICALS | $44,137,000 | +39.1% | 1,162,730 | +3.8% | 1.68% | +17.8% |
| GEVA | Buy | SYNAGEVA BIOPHARMA | $35,665,000 | +5.6% | 365,684 | +0.5% | 1.35% | -10.6% |
| MDT | New | MEDTRONIC PLCshares | $31,830,000 | – | 408,126 | +100.0% | 1.21% | – |
| ACHN | Buy | ACHILLION PHARMACEUTICALS | $31,459,000 | +8.2% | 3,190,572 | +34.4% | 1.20% | -8.4% |
| ALDR | Buy | ALDER BIOPHARMACEUTICALS | $30,951,000 | +920.1% | 1,072,437 | +928.2% | 1.18% | +764.0% |
| RLYP | Buy | RELYPSA INC | $30,221,000 | +20.9% | 837,830 | +3.3% | 1.15% | +2.4% |
| UTHR | Buy | UNITED THERAPEUTICS | $30,190,000 | +43.1% | 175,080 | +7.5% | 1.15% | +21.1% |
| SGNT | Buy | SAGENT PHARMACEUTICALS | $27,204,000 | +29.9% | 1,170,083 | +40.3% | 1.03% | +10.0% |
| DXCM | Buy | DEXCOM INC | $24,908,000 | +58.2% | 399,558 | +39.7% | 0.95% | +34.0% |
| MNTA | Buy | MOMENTA PHARMACEUTICALS | $24,077,000 | +37.0% | 1,584,010 | +8.5% | 0.91% | +16.0% |
| ALGN | Buy | ALIGN TECH INC | $23,296,000 | +34.8% | 433,140 | +40.2% | 0.88% | +14.2% |
| ABT | Buy | ABBOTT LABS | $22,441,000 | +23.0% | 484,376 | +19.5% | 0.85% | +4.0% |
| AKRXQ | Buy | AKORN INC | $22,171,000 | +41.0% | 466,668 | +7.4% | 0.84% | +19.4% |
| TTPH | New | TETRAPHASE PHARMAC | $22,182,000 | – | 605,393 | +100.0% | 0.84% | – |
| KPTI | Buy | KARYOPHARM THERAPEUTICS | $21,649,000 | +9.1% | 707,268 | +33.5% | 0.82% | -7.6% |
| NXTM | Buy | NXSTAGE MEDICAL | $15,156,000 | +4.7% | 876,042 | +8.6% | 0.58% | -11.2% |
| NVTA | New | INVITAE CORP | $14,655,000 | – | 874,391 | +100.0% | 0.56% | – |
| ASND | New | ASCENDIS PHARMA A Ssp adr | $12,694,000 | – | 731,660 | +100.0% | 0.48% | – |
| HCA | Buy | HCA HLDGS INC | $12,577,000 | +19.0% | 167,176 | +16.1% | 0.48% | +0.8% |
| NVS | Buy | NOVARTIS AGsp adr | $11,775,000 | +100.1% | 119,405 | +88.0% | 0.45% | +69.3% |
| AMPH | Buy | AMPHASTAR PHARMACEUTICALS | $10,980,000 | +43.2% | 733,932 | +11.2% | 0.42% | +21.2% |
| NVO | Buy | NOVO-NORDISK ASadr | $10,399,000 | +32.6% | 194,775 | +5.1% | 0.40% | +12.2% |
| CI | New | CIGNA CORP | $9,898,000 | – | 76,465 | +100.0% | 0.38% | – |
| ZSPH | Buy | ZS PHARMA INC | $9,228,000 | +363.5% | 219,303 | +357.9% | 0.35% | +293.3% |
| UHS | Buy | UNIVERSAL HEALTH SVCclass b | $7,762,000 | +13.1% | 65,939 | +6.9% | 0.30% | -4.2% |
| TGTX | New | TG THERAPEUTICS | $6,751,000 | – | 436,084 | +100.0% | 0.26% | – |
| ARAY | Buy | ACCURAY INC | $2,113,000 | +23.6% | 227,195 | +0.4% | 0.08% | +3.9% |
| IPXL | New | IMPAX LABS INC | $1,861,000 | – | 39,697 | +100.0% | 0.07% | – |
| LCI | New | LANNET INC | $1,736,000 | – | 25,634 | +100.0% | 0.07% | – |
| ENDP | New | ENDO INTL PLCshares | $1,676,000 | – | 18,688 | +100.0% | 0.06% | – |
| JAZZ | New | JAZZ PHARMA PLC | $1,625,000 | – | 9,405 | +100.0% | 0.06% | – |
| VRX | Buy | VALEANT PHARMACEUTICALS INTL | $1,609,000 | +523.6% | 8,101 | +350.1% | 0.06% | +408.3% |
| WX | Buy | WUXI PHARMATECH ADSsp adr | $1,577,000 | +16.0% | 40,653 | +0.7% | 0.06% | -1.6% |
| MCK | New | MCKESSON CORP | $1,582,000 | – | 6,995 | +100.0% | 0.06% | – |
| EARS | New | AURIS MED HLDG AG | $1,497,000 | – | 279,850 | +100.0% | 0.06% | – |
| IMDZ | Buy | IMMUNE DESIGN CORP | $1,417,000 | +117.3% | 67,127 | +216.9% | 0.05% | +86.2% |
| ALKS | New | ALKERMES PLCshares | $1,388,000 | – | 22,770 | +100.0% | 0.05% | – |
| HZNP | New | HORIZON PHARMAshares | $1,337,000 | – | 51,476 | +100.0% | 0.05% | – |
| PCRX | New | PACIRA PHARMACEUTICALS | $1,238,000 | – | 13,939 | +100.0% | 0.05% | – |
| DEPO | New | DEPOMED INC | $1,224,000 | – | 54,632 | +100.0% | 0.05% | – |
| EGRX | New | EAGLE PHARMACEUTICALS | $927,000 | – | 22,123 | +100.0% | 0.04% | – |
| NKTR | New | NEKTAR THERAPEUTICS | $870,000 | – | 79,115 | +100.0% | 0.03% | – |
| CBM | New | CAMBREX CORP | $463,000 | – | 11,673 | +100.0% | 0.02% | – |
| CTLT | New | CATALENT INC | $445,000 | – | 14,293 | +100.0% | 0.02% | – |
| CHRS | New | COHERUS BIOSCIENCES | $387,000 | – | 12,656 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOMARIN PHARMAC INC | 45 | Q2 2024 | 6.7% |
| DR REDDYS LABS LTD | 45 | Q2 2024 | 2.0% |
| PTC THERAPEUTICS INC | 43 | Q2 2024 | 2.7% |
| GILEAD SCIENCES INC | 41 | Q2 2024 | 8.4% |
| VERTEX PHARMACEUTICL | 41 | Q2 2024 | 6.0% |
| INCYTE CORPORATION | 41 | Q2 2024 | 5.2% |
| AMICUS THERAPEUTICS INC | 40 | Q2 2024 | 6.6% |
| PFIZER INC | 38 | Q2 2024 | 6.3% |
| MERCK & CO. INC | 37 | Q2 2024 | 6.4% |
| MEDTRONIC PLC | 36 | Q2 2024 | 4.4% |
View SECTORAL ASSET MANAGEMENT INC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| eFFECTOR Therapeutics, Inc. | February 14, 2024 | 2,382,644 | 3.7% |
| Galera Therapeutics, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
| Aprea Therapeutics, Inc. | February 12, 2021 | 163,681 | 0.8% |
| LA JOLLA PHARMACEUTICAL CO | February 13, 2020 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 13, 2018 | 1,426,862 | 4.4% |
| Advaxis, Inc. | February 10, 2017 | 690,074 | 1.7% |
| AMICUS THERAPEUTICS INC | February 10, 2017 | 5,100,198 | 3.6% |
| OncoMed Pharmaceuticals Inc | February 12, 2016 | ? | ? |
| IRONWOOD PHARMACEUTICALS INC | February 13, 2015 | ? | ? |
| SEQUENOM INC | February 12, 2014 | ? | ? |
View SECTORAL ASSET MANAGEMENT INC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-08-13 |
| N-PX | 2024-08-09 |
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-13 |
View SECTORAL ASSET MANAGEMENT INC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.